All Stories

  1. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
  2. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients
  3. Prognostic factors for multiple myeloma in the era of novel therapies
  4. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis
  5. Treating ALK-positive non-small cell lung cancer
  6. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
  7. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis
  8. POEMS Syndrome
  9. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
  10. An overview of the role of carfilzomib in the treatment of multiple myeloma
  11. Gefitinib: an “orphan” drug for non-small cell lung cancer
  12. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
  13. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
  14. Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia
  15. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
  16. Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study
  17. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma
  18. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens
  19. When to recommend a second autograft in patients with relapsed myeloma?
  20. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
  21. Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma
  22. Carfilzomib for treating myeloma
  23. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment
  24. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis
  25. Predicting the Outcome of Sjogren’s Syndrome-Associated Non-Hodgkin’s Lymphoma Patients
  26. Asymptomatic Bacteriuria in Women With Autoimmune Rheumatic Disease: Prevalence, Risk Factors, and Clinical Significance
  27. Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10
  28. Intestinal Upregulation of Melanin-Concentrating Hormone in TNBS-Induced Enterocolitis in Adult Zebrafish
  29. Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis
  30. Increased Susceptibility of Melanin-Concentrating Hormone-Deficient Mice to Infection with Salmonella enterica Serovar Typhimurium
  31. Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome
  32. Reduced Intestinal Tumorigenesis in APCmin Mice Lacking Melanin-Concentrating Hormone
  33. The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates
  34. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis
  35. Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies
  36. Evidence of Association BetweenMethylenetetrahydrofolate ReductaseGene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population
  37. Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin cytoskeleton regulation and cell cycle): the CUMAGAS-BMD information system
  38. Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA
  39. A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly
  40. You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice
  41. T1904 Predictors and Patterns of the Placebo Response in Gastro-Esophageal Reflux Disease: Meta-Analysis of Clinical Trials
  42. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease
  43. Field Synopsis and Synthesis of Genetic Association Studies in Osteoarthritis: The CUMAGAS-OSTEO Information System
  44. Serum correlates of the placebo effect in irritable bowel syndrome
  45. MTHFRgene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis
  46. Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement